NS-105, LAM-105 · Evidence-based safety and harm-reduction overview.
| Also known as | NS-105, LAM-105 |
| Category | Nootropic |
| controlled_status | Unscheduled US (unapproved) |
| approval_status | Not FDA-approved for general use; some limited human trials completed |
| research_focus | ADHD in specific genetic subgroups, dementia (discontinued) |
| US legal status | Fasoracetam is an experimental research chemical that is not FDA-approved for general use in the United States. It has been investigated in clinical trials for specific conditions but is sold online as an unregulated nootropic not authorized for over-the-counter human consumption. |
Fasoracetam is a synthetic compound in the racetam class that acts on metabotropic glutamate receptors and other systems. It was originally investigated for dementia and has been studied more recently in trials related to ADHD in certain genetic subgroups.
Research suggests fasoracetam acts primarily on metabotropic glutamate receptors (mGluRs), particularly through allosteric modulation that enhances agonist-induced responses. Studies also indicate effects on acetylcholine and GABA signaling and possible neuroprotective properties, though detailed human mechanisms remain incompletely characterized.
Fasoracetam was developed in Japan in the 1990s as part of the aniracetam family and was investigated for dementia and cognitive disorders. More recent research examined its effects in ADHD patients with specific genetic variants, but it has never been approved by the FDA for any indication.
Research suggests fasoracetam acts on metabotropic glutamate receptors and influences acetylcholine and GABA signaling, based largely on preclinical work. Some human clinical trials have been conducted, including for ADHD in patients with specific glutamate-receptor gene variants, but published human efficacy data remain limited and the broader evidence base is scant.
In clinical trials, fasoracetam has been studied at doses ranging from 100-400 mg daily divided into two to four doses. Trials for ADHD-related indications used multiple-dose regimens, but optimal dosing for any indication remains undetermined.
This is general research/context information, not medical advice or a recommended protocol.
Fasoracetam combinations with other neuroprotective or glutamate-modulating compounds are not studied. Medical supervision is necessary before attempting any combination use.
If you are going to research a compound, verifying identity and purity is the single most protective step. Independent analytical testing and sterile-handling supplies reduce risk.
Compare testing optionsYes, in limited clinical trials including for ADHD in specific genetic subgroups, but published human data remain scant.
No. It is not approved for general use and is sold as an unregulated nootropic, not authorized for over-the-counter consumption.
We do not provide dosing guidance. Given its experimental status, consult a qualified clinician.
Research is extremely limited. Some trials examined ADHD in people with specific genetic variants, but any benefit remains unproven.
Interactions with most medications are not studied. Do not combine without explicit medical supervision and careful drug-interaction review.
No published long-term safety or efficacy studies exist; any use beyond short research-trial durations is experimental.
Medical & legal disclaimer. This site is for informational and harm-reduction purposes only. It is not medical advice and is not a substitute for a licensed healthcare professional. The compounds discussed are largely not approved by the FDA for human use and many are sold strictly as research chemicals 'not for human consumption.' Nothing here is an endorsement to purchase, possess, or use any substance. Laws vary by jurisdiction. Always consult a qualified physician and follow the law where you live.
Some links on this page may be affiliate links. If you buy through them we may earn a commission at no extra cost to you. This never changes the safety information we publish.